The Interplay of Reactive Oxygen Species, Hypoxia, Inflammation, and Sirtuins in Cancer Initiation and Progression.
Tafani M, Sansone L, Limana F, Arcangeli T, De Santis E, Polese M, Fini M, Russo MA. · 2016
Read The Interplay of Reactive Oxygen Species, Hypoxia, Inflammation, and Sirtuins in Cancer Initiation and Progression. by Tafani M, Sansone L, Limana F, Arcangeli T, De Santis E, Polese M, Fini M, Russo MA. (2016) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc4699039.txt.
Introduction
Marco Tafani, Luigi Sansone, Federica Limana, and five colleagues traced how reactive oxygen species drive cancer, in Oxidative Medicine and Cellular Longevity in 2016. These reactive molecules, called ROS, are a constant byproduct of cells using oxygen. Cancer cells make extra amounts, and ROS play a part at every stage of a tumor's life, from the first change to later spread. The review sets out to reconcile reports that ROS both harm and help.
Attention centers on three control systems: the oxygen sensor HIF, the inflammation switch NF-kappaB, and the sirtuin family of enzymes. ROS feed into each, linking low oxygen, inflammation, and cell aging signals into one story of tumor growth. The authors fit the known hallmarks of cancer into a step-by-step sequence. Their sketch gives readers a single map of how one chemical force threads through cancer's whole course.
Catalog record
| CREATOR | Tafani M, Sansone L, Limana F, Arcangeli T, De Santis E, Polese M, Fini M, Russo MA. |
|---|---|
| YEAR | 2016 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 92 KB |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |
Browse the full library · About the Tower of Babel
Full text
The opening of the work, from the library's hosted text:
The Interplay of Reactive Oxygen Species, Hypoxia, Inflammation, and Sirtuins in Cancer Initiation and Progression By Marco Tafani, Luigi Sansone, Federica Limana, Tania Arcangeli, Elena De Santis, Milena Polese, Massimo Fini, Matteo A Russo Published in: Oxidative Medicine and Cellular Longevity DOI: 10.1155/2016/3907147 ABSTRACT Abstract The presence of ROS is a constant feature in living cells metabolizing O2. ROS concentration and compartmentation determine their physiological or pathological effects. ROS overproduction is a feature of cancer cells and plays several roles during the natural history of malignant tumor. ROS continuously contribute to each step of cancerogenesis, from the initiation to the malignant progression, acting directly or indirectly. In this review, we will (a) underline the role of ROS in the pathway leading a normal cell to tumor transformation and progression, (b) define the multiple roles of ROS during the natural history of a tumor, (c) conciliate many conflicting data about harmful or beneficial effects of ROS, (d) rethink the importance of oncogene and tumor suppressor gene mutations in relation to the malignant progression, and (e) collocate all the cancer hallmarks in a mechanistic sequence which could represent a “physiological” response to the initial growth of a transformed stem/pluripotent cell, defining also the role of ROS in each hallmark. We will provide a simplified sketch about the relationships between ROS and cancer. The attention will be focused on the contribution of ROS to the signaling of HIF, NFκB, and Sirtuins as a leitmotif of cancer initiation and progression. 1. INTRODUCTION ROS (Reactive Oxygen Species) production has been strictly associated with cancer [1], ageing [2], diabetes [3], obesity [4], neurodegeneration [5], and other age-related diseases such as age-related retinopathy, cochlear degeneration, and chronic inflammatory diseases [6]. How can ROS contribute to so many apparently different clinical entities and what are the common molecular targets and pathways altered by ROS? In recent years, a great amount of information has been produced to answer these questions. Interestingly, such information stems from the study of the roles of ROS along the tumorigenesis sequence [7]. The complexity of relationships between ROS and cancer pathogenesis is primarily due to the diverse species of ROS produced by O2 metabolism and their properties, such as chemical nature, half-life, reactivity and specificity for their biological targets, ability to diffuse and travel among subcellular compartments, type of changes produced in target molecules, and, finally, the importance of affected biological functions [8]. Moreover, it is difficult to identify the molecular targets and the numerous redundant pathways modified by ROS, with a significant role in cancerogenesis. Besides, biologically active or toxic concentrations of ROS resulting from the ratio between production and detoxification introduce additional important variables to be considered in describing the ROS/cancer relationships [9]. Cancer pathogenesis may be described as a multistep process including transformation, growth promotion and, in clinically evident tumors, malignant progression [10]. During the natural history of cancer a large number of genes, molecules, and pathways contribute first to transformation and promotion then to the manifestation of the malignant cancer phenotype; most of these molecules and pathways interact with ROS in the cytosol, nucleoplasm, and intraorganellar space. A transformed cell is identified by the loss of control of proliferation and deregulation of apoptosis producing an excess of cell number and forming a mass (tumor). The disruption of cell cycle and apoptosis regulation is due to mutations of genes with a gain-of-function (oncogenes) and a loss-of-function (oncosuppressor genes), both leading to an excessive proliferative signal [11, 12]. The deregulation of apoptosis is due to mutations of genes involved in the signaling controlling programmed cell death, with a gain-of-function of genes (oncogenes) protecting from apoptosis and a loss-of-function (oncosuppressor genes) promoting apoptosis. Upstream, alterations of DNA repair mechanisms may often facilitate the accumulation of crucial mutations in a single stem cell giving rise to the transformed stem cell responsible for the growth of the early small tumor [13]. The initial growth of a small tumor occurs with absent, insufficient, or abnormal angiogenesis. This produces areas of hypoxia of different severity in which ROS increases, favoring tumor cell survival, adaptation, and progression [14]. Even though the precise mechanism through which hypoxia increases ROS is still a matter of debate, it seems that ROS production is due to the effects of hypoxia on the mitochondria electron transport chain (ETC). In particular, hypoxia would drive ROS increase by acting on complexes I, II, and III of the ETC [15, 16]. In fact, the use of inhibitors for each one of these complexes resulted in the inhibition of ROS accumulation [15, 16]. Moreover, such ROS are mainly represented by H2O2 since forced expression of catalase or glutathione peroxidase-1 completely reversed hypoxia-induced ROS expression in isolated pulmonary artery myocytes [15, 16]. Interestingly, hypoxia-driven ROS increase would then leave the mitochondria causing destabilization of Prolyl Hydroxylases (PHD) and stabilization of HIF1α [15, 16]. HIF is the major transcription factor responsible for triggering tumor progression [17]. In addition, in this phase, ROS further increases contributing to the involvement of NFκB and Sirtuins in the full acquisition of malignant phenotype [18]. Here we will shortly review the contributions and mechanisms of ROS from cell transformation to the acquisition of every single hallmark of a clinically significant malignant tumor, trying to correlate specific molecular targets to ROS role. 2. ROS COMPARTMENTATION AND PRODUCTION Five main compartments contain ROS: mitochondria, cytosol, single membrane-bound organelles (peroxisomes, endosomes, and phagosomes), exosomes released by plasma membranes by shedding, and extracellular fluids including plasma [9]. As schematized in Table 1 and Figure 1, ROS are produced in different subcellular compartments by the action of different enzymes and then they can travel through channels or vesicles. In particular, mitochondria produce large amount of ROS that can be either detoxified or can leave the organelle through channels such as voltage dependent anion channel (VDAC) or aquaporin. Similarly ROS can be produced by NADPH-oxidases (NOX) and other cytosolic enzymes as well as by peroxisomes. Finally, ROS can be released in the extracellular space through aquaporin or exosomes (Figure 1). [Table: Classes of ROS and their properties.] [Figure: Subcellular compartmentation of ROS. 1. Mitochondrial ROS which can travel to cytoplasm through VDAC (superoxide) or through aquaporin (peroxides). 2. Cytosolic ROS. 3. Redoxosomes, such as peroxisomes and endoplasmic reticulum derived vesicles. 4. ROS included into exosomes and vesicles shedding from damaged plasma membranes. 5. Extracellular ROS in extracellular fluids and plasma, partly crossing the plasma membrane through aquaporin, partly secreted with granules (i.e., activated leukocytes).] Three broad classes of ROS may be produced: hydroxyl radicals, superoxides, and hydroperoxides, with distinctive characteristics regarding their reactivity, half-life, target specificity, localization, and, very importantly, biological and pathological effects (Table 1). At present, the acronym ROS may include also several nitrogen-containing compounds or RNS (Reactive Nitrogen Species), such as nitric oxide (NO), nitroxyl anion (NO−), and peroxynitrite (ONOO−). NO is produced by the activity of inducible nitric oxide synthase (iNOS) and reacts with superoxide to give rise to the other RNS. ROI (Reactive Oxygen Intermediates) and RNI (Reactive Nitrous Intermediate) are additional acronyms used to indicate ROS [8, 19]. ROS are produced in the mitochondria as by-products of fatty acid (FA) metabolism and oxidative phosphorylation for ATP synthesis [8, 19]. Hydroxyl anion half-life is extremely